Our research group focuses on finding and exploiting novel molecular targets for prognosis and therapy in patients with thyroid cancer. We use cancer cell lines, primary cells from patients with cancer, animal models and some clinical trials. Our primary work is using molecular biology tools in cell culture and animal models as preclinical studies that develop into pivotal phase I/II clinical trials. Currently, we are studying NFkB signaling, the Src-FAK pathway and cancer metabolism in advanced thyroid cancer as a model system. Our group is also exploring the role of the immune system in thyroid cancer progression.